Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey

Autor: Philip Scheltens, Henrike Wolf, Daniela Bertens, R. C. Petersen, Ineke van Rossum, Pieter Jelle Visser, Patrick G. Kehoe, Flavio Nobili, Michael T. Heneka, José Luis Molinuevo, Alexandre de Mendonça, Stephanie J.B. Vos, Jacub Hort
Přispěvatelé: Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Neurology, Amsterdam Neuroscience - Neurodegeneration
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Pediatrics
Neurology
Disease
GUIDELINES
lcsh:RC346-429
0302 clinical medicine
Surveys and Questionnaires
Survey
Cognitive impairment
DEMENTIA
diagnosis [Alzheimer Disease]
Cognition
ASSOCIATION
Middle Aged
3. Good health
Patient management
Europe
ALZHEIMERS-DISEASE
Female
MCI
MCI due to AD
Prodromal AD
Questionnaire
medicine.medical_specialty
Attitude of Health Personnel
Cognitive Neuroscience
BIOMARKERS
Prodromal Symptoms
DIAGNOSIS
behavioral disciplines and activities
lcsh:RC321-571
03 medical and health sciences
Alzheimer Disease
mental disorders
MANAGEMENT
medicine
Humans
Dementia
Cognitive Dysfunction
ddc:610
Clinical care
lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry
lcsh:Neurology. Diseases of the nervous system
business.industry
Research
medicine.disease
nervous system diseases
030104 developmental biology
diagnosis [Cognitive Dysfunction]
Neurology (clinical)
business
human activities
030217 neurology & neurosurgery
Geriatric psychiatry
Zdroj: Alzheimer's Research & Therapy, 11(1):74. BioMed Central Ltd
Bertens, D, Vos, S, Kehoe, P, Wolf, H, Nobili, F, Mendonça, A, van Rossum, I, Hort, J, Molinuevo, J L, Heneka, M, Petersen, R, Scheltens, P & Visser, P J 2019, ' Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: A European survey ', Alzheimer's Research and Therapy, vol. 11, no. 1, 74 . https://doi.org/10.1186/s13195-019-0525-9
Alzheimer's Research and Therapy, 11(1):74. BioMed Central
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-12 (2019)
Bertens, D, Vos, S, Kehoe, P, Wolf, H, Nobili, F, Mendonça, A, van Rossum, I, Hort, J, Molinuevo, J L, Heneka, M, Petersen, R, Scheltens, P & Visser, P J 2019, ' Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care : a European survey ', Alzheimer's Research and Therapy, vol. 11, 74 (2019) . https://doi.org/10.1186/s13195-019-0525-9
Alzheimer's Research & Therapy
Alzheimer's research & therapy 11(1), 74 (2019). doi:10.1186/s13195-019-0525-9
ISSN: 1758-9193
Popis: Introduction The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer’s disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. Methods An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer’s Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. Results Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients’ wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. Conclusions The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication. Electronic supplementary material The online version of this article (10.1186/s13195-019-0525-9) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: